Form 4: Nuvalent Director Christy Oliger Receives Equity Grant Valued at Over $750,000

Nuvalent, Inc. Director Christy J. Oliger was granted 3,971 restricted stock units and options to purchase 6,119 shares of Class A Common Stock, aligning her interests with shareholders.

Summary

• Christy J. Oliger, a Director of Nuvalent, Inc. (NUVL), reported an acquisition of equity securities.
• On June 18, 2025, Ms. Oliger was granted 3,971 shares of Nuvalent, Inc. Class A Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.00 per share.
• These RSUs will vest in three equal annual installments starting from June 18, 2025, contingent upon her continued service to the company.
• Additionally, on June 18, 2025, Ms. Oliger was granted stock options to purchase 6,119 shares of Class A Common Stock with an exercise price of $75.53 per share.
• These stock options will vest over three years following June 18, 2025, in equal monthly installments, also subject to her continued service.
• The options have an expiration date of June 18, 2035.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as the equity grant aligns the director's interests with shareholders, which is generally viewed favorably. However, it's a routine compensation event and not indicative of significant operational or financial news.

Positives

• The equity grants to Director Christy J. Oliger align her financial interests directly with the long-term performance and success of Nuvalent, Inc. and its shareholders.
• The grants represent a standard form of compensation for directors, indicating stable corporate governance practices.

Future Outlook

The granted Restricted Stock Units (RSUs) and stock options are subject to vesting schedules over the next three years, contingent on the director's continued service to Nuvalent, Inc., indicating an expectation of ongoing commitment.

Industry Context

The granting of equity, such as Restricted Stock Units and stock options, to directors is a common and widely accepted practice across various industries, including biotechnology and pharmaceuticals, to incentivize long-term commitment and align leadership interests with shareholder value.

Comparison to Industry Standards

• The structure of equity compensation, including RSUs and stock options with multi-year vesting schedules, is a standard practice for director remuneration in publicly traded companies, particularly within the life sciences sector.
• The document does not provide specific comparable companies, projects, or results to allow for a detailed quantitative comparison of the compensation package against industry benchmarks.

Related Party Transactions

• The equity grant to Christy J. Oliger, a director of Nuvalent, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors. This is a standard form of director compensation.

Stakeholder Impact

• Shareholders: The equity grants are designed to align the director's interests with those of the shareholders, potentially leading to more shareholder-centric decision-making.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Continued service of Christy J. Oliger to Nuvalent, Inc. for the RSUs and stock options to vest according to their respective schedules.

Key Dates

Keywords

Nuvalent, NUVL, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Corporate Governance